NewsMakers in the Biotech Industry Conference

RNS Number : 1299J

Scancell Holdings Plc

07 September 2016

 

7 September 2016

Scancell Holdings Plc

("Scancell" or the "Company")

Scancell to present at the 23rd Annual NewsMakers in the Biotech Industry Conference in NYC

Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that it will be presenting at the 23rd Annual NewsMakers in the Biotech Industry Conference. The conference is being held on 9 September 2016 at the Millennium Broadway Hotel & Conference Center in New York City, USA.

Dr John Chiplin, Executive Chairman of Scancell, will be presenting an overview of the Company at 15:00 ET in presentation room 311 and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

For Further Information:

Scancell Holdings Plc

Dr John Chiplin, Executive Chairman Dr Richard Goodfellow, CEO	Scancell Holdings Plc	[phone] [phone]
Freddy Crossley (Corporate Finance) Tom Salvesen (Corporate Broking)	Panmure Gordon & Co	[phone] [phone]
Mo Noonan/Simon Conway	FTI Consulting	[phone]

About NewsMakers in the Biotech Industry Conference

NewsMakers presents a hand-picked group of public biotech companies whose corporate and regulatory milestones will drive stock prices. NewsMakers is recognized as the industry's key venue for companies to take their story to Wall Street each Fall. Thus, NewsMakers remains the best opportunity for business development executives and key members of the institutional investment and analyst communities to compare notes and assess the industry landscape.

Last year, more than 500 delegates congregated at NewsMakers, including money managers who controlled more than $480 billion in equity assets, with over $50 billion dedicated to healthcare and $15 billion dedicated to biotech.

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

 

END

 

 

NRAUGUGUBUPQGMQ